BetterLife Pharma Provides Scientific Update on Neuroplastogenic Activity of BETR-001
(CNSX:BETR.CN),(Boerse Frankfurt – Freiverkehr:NPAU),(OTC US:BETRF),(Other OTC:BETRF),(Boerse Frankfurt – Freiverkehr:NPAU.F), VANCOUVER, British Columbia, May 28, 2025 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic neuroplastogen in the treatment of psychiatric and neurological disorders, […]